CHMP meeting highlights – July 2024
In its July meeting, the EMA’s human medicines committee recommended 14 medicines and held a negative opinion for authorising lecanemab to treat Alzheimer’s disease.
List view / Grid view
In its July meeting, the EMA’s human medicines committee recommended 14 medicines and held a negative opinion for authorising lecanemab to treat Alzheimer’s disease.
12 July 2016 | By Victoria White, Digital Content Producer
With this approval, Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition...